Month: June 2016

Predicting cardiotoxicity with engineered 3D human cardiac tissue models

Contact details: Ayla Annac, CEO/President of lnvivoSciences Inc.  +1-608-628-8035. aannac@ Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardio­vascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. These statistics demonstrate the need to address a patient’s specific genetic make-up and…
Read more